Drugs / Copper Cu 64 PSMA I&T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06235099 | Apr 2024 → Feb 2025 | prostate adenocarcinoma | Curium US LLC | Completed | No outcome recorded |
| Phase 3 | NCT06235151 | Apr 2024 → Sep 2026 overdue | prostate adenocarcinoma | Curium US LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-15 | Curium US LLC | Results Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T curiumpharma.com ↗
Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA I&T in patients with histologically-proven metastatic prostate cancer. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Cu 64 PSMA I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06235099 ↗ |
| Modality | Diagnostic / imaging agent | “Radiopharmaceutical PET imaging tracer” NCT06235099 ↗ |
| Route | Intravenous | “injected intravenously” NCT06235099 ↗ |